Vertex Pharmaceuticals Inc (VRTX) 87.53 $VRTX
Vertex Receives European Approval for KALYDECO(TM) (ivacaftor) in Eight Non-G551D Gating Mutations
Business Wire - Thu Jul 31, 3:18PM CDT
---KALYDECO is the first medicine to treat the underlying cause of CF in people with specific non-G551D gating mutations-
Vertex Pharmaceuticals Set to Possibly Rebound After Yesterday's Selloff of 3.71%
Comtex SmarTrend(R) - Wed Jul 30, 4:24PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $91.31 to a high of $95.24. Yesterday, the shares fell 3.7%, which took the trading range below the 3-day low of $94.67 on volume of 2.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Vertex Pharmaceuticals Posts Wider Q2 Loss, Maintains View - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 30, 12:10PM CDT
Vertex Pharma (VRTX) posted a wider second quarter loss and also missed revenue expectations.
Vertex Pharma posts bigger 2Q loss
AP - Tue Jul 29, 4:07PM CDT
BOSTON (AP) — Vertex Pharmaceuticals Inc. on Tuesday reported a wider loss in its second quarter, and beat analysts' expectations.
Vertex Reports Second Quarter 2014 Financial Results and Provides Updates on Key Research and Development Programs
Business Wire - Tue Jul 29, 3:01PM CDT
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended June 30, 2014. Vertex reported total second quarter 2014 revenues of $138 million, including revenues of $113 million from KALYDECO(R) (ivacaftor). The GAAP net loss for the second quarter of 2014 was $(159) million, or $(0.68) per share. The non-GAAP net loss for the second quarter of 2014 was $(142) million, or $(0.61) per share. As of June 30, 2014, Vertex had $1.22 billion in cash, cash equivalents and marketable securities. In July 2014, Vertex entered into a credit agreement that provides for a secured loan of up to $500 million, $300 million of which Vertex received in July 2014, which adds to the company's cash balance. Vertex also reiterated its financial guidance for total 2014 non-GAAP revenues, 2014 KALYDECO revenues and non-GAAP operating expenses. The company also provided updates on its key research and development programs in cystic fibrosis (CF).
Stock Market News for July 29, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Jul 29, 9:10AM CDT
Benchmarks ended Monday’s choppy trading session little changed as investors assessed new deals and discouraging housing data
Will Vertex Pharmaceuticals (VRTX) Loss be Below Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 28, 3:30PM CDT
Vertex Pharmaceuticals Inc. (VRTX) is scheduled to report second quarter 2014 results after market close on Jul 29.
Should You Buy Vertex Pharmaceuticals (VRTX) Ahead of Earnings? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 28, 7:48AM CDT
Analysts raising estimates right before earnings is a pretty good indicator of some favorable trends underneath the surface for Vertex Pharmaceuticals.
Global Rheumatoid Arthritis Drugs Market 2014-2018
M2 - Mon Jul 28, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tv2rn2/global_rheumatoid) has announced the addition of the "Global Rheumatoid Arthritis Drugs Market 2014-2018" report to their offering. RA is a chronic disease that leads to inflammation and pain in the human body's joints such as wrists, fingers, knees, feet, and ankles. In addition, it causes inflammation of the tissues that surround the joints and in other organs. The symptoms of RA begin slowly, usually just mild pain around the joints coupled with stiffness and fatigue, and in the later stages it causes inflammation of the joints. It can occur at any age, even in children, which is called juvenile arthritis. The disease is three times more common in women than in men. Genetic and environmental elements are known to contribute in the development of RA. The analysts forecast the Global Rheumatoid Arthritis Drugs market will grow at a CAGR of 4.09 percent over the period 2013-2018. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Competitive Assessment of Top Drugs 08. Five Forces Analysis 09. Market Segmentation by Category 10. Geographical Segmentation 11. Buying Criteria 12. Rate of Incidence and Prevalence 13. Pipeline Snapshot 14. Market Growth Drivers 15. Drivers and their Impact 16. Market Challenges 17. Impact of Drivers and Challenges 18. Market Trends 19. Trends and their Impact 20. Vendor Landscape 21. Key Vendor Analysis 22. Other Reports in this Series Companies Mentioned: - AbbVie Inc. - Amgen Inc. - Bristol-Myers Squibb Co. - F. Hoffmann-La Roche Ltd. - Janssen Pharmaceuticals Inc. - Pfizer Inc. - AB Science SA - Astellas Pharma Inc. - AstraZeneca plc - Biogen Idec Inc. - Boehringer Ingelheim GmbH - Celgene Corp. - Daiichi Sankyo Co. Ltd. - Eli Lilly & Co. - GE Healthcare Co. - Genmab A/S - GSK plc - Incyte Corp. - Merck & Co. Inc. - Mitsubishi Tanabe Pharma Corp. - Novartis AG - Novo Nordisk A/S - Rigel Pharmaceuticals Inc. - Sanofi - Takeda Pharmaceutical Co. Ltd. - UCB SA - Vertex Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/tv...rheumatoid
MONDAY DEADLINE: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Vertex Pharmaceuticals Incorporated and Its Board of Directors and a Lead Plaintiff Deadline of July 28, 2014 -- VRTX
Business Wire - Fri Jul 25, 6:04PM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who purchased Vertex Pharmaceuticals Incorporated ("Vertex" or the "Company"
(NasdaqGS:VRTX) securities between May 7, 2012 and May 29, 2012.
INVESTOR ALERT: Class Action Lawsuit Against Vertex Pharmaceuticals Incorporated Announced by Law Offices of Howard G. Smith
Business Wire - Wed Jul 23, 12:23PM CDT
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of all purchasers of the common stock of Vertex Pharmaceuticals Incorporated ("Vertex" or the "Company" (NASDAQ:VRTX) between May 7, 2012 and May 29, 2012, inclusive (the "Class Period" .
SmarTrend Watching for Potential Pullback in Shares of Vertex Pharmaceuticals After 1.48% Gain
Comtex SmarTrend(R) - Tue Jul 22, 5:13PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $95.75 to a high of $98.08. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $97.78 on volume of 1.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Vertex Pharmaceuticals Rises 1.48% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Jul 22, 5:11PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $95.75 to a high of $98.08. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $97.78 on volume of 1.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SHAREHOLDER ALERT: Brower Piven Encourages Investors With Losses Over $100,000 In Vertex Pharmaceuticals Incorporated To Contact The Firm Before The Lead Plaintiff Deadline In Class Action Lawsuit -- VRTX
GlobeNewswire - Tue Jul 22, 4:44PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of purchasers of Vertex Pharmaceuticals Incorporated ("Vertex" or the "Company" (Nasdaq:VRTX) common stock during the period between May 7, 2012 and May 29, 2012, inclusive (the "Class Period" , and informs investors who wish to become proactively involved in the litigation that they have until July 28, 2014 to seek appointment as lead plaintiff.
Biotech Stock Roundup: AbbVie Woos Shire with Revised Offer, Sarepta Slips on Eteplirsen Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 16, 8:49AM CDT
Focus last week remained on AbbVie's (ABBV) attempts to acquire Shire (SHPG) - the company came back with a revised offer which could very well be accepted by Shire.
SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Vertex Pharmaceuticals Incorporated and Its Board of Directors and a Lead Plaintiff Deadline of July 28, 2014 -- VRTX
GlobeNewswire - Wed Jul 16, 3:52AM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who purchased Vertex Pharmaceuticals Incorporated ("Vertex" or the "Company" (Nasdaq:VRTX) securities between May 7, 2012 and May 29, 2012.
INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against Vertex Pharmaceuticals Incorporated
Business Wire - Tue Jul 15, 7:32AM CDT
Glancy Binkow & Goldberg LLP reminds investors of Vertex Pharmaceuticals Incorporated ("Vertex" or the "Company" (NASDAQ:VRTX) that all purchasers of Vertex common stock between May 7, 2012 and May 29, 2012, inclusive (the "Class Period" have until July 28, 2014, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit.
Vertex Receives European Approval for KALYDECO(TM) (ivacaftor) in Eight Non-G551D Gating Mutations
Business Wire - Thu Jul 31, 3:18PM CDT
---KALYDECO is the first medicine to treat the underlying cause of CF in people with specific non-G551D gating mutations-
Vertex Pharmaceuticals Set to Possibly Rebound After Yesterday's Selloff of 3.71%
Comtex SmarTrend(R) - Wed Jul 30, 4:24PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $91.31 to a high of $95.24. Yesterday, the shares fell 3.7%, which took the trading range below the 3-day low of $94.67 on volume of 2.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Vertex Pharmaceuticals Posts Wider Q2 Loss, Maintains View - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 30, 12:10PM CDT
Vertex Pharma (VRTX) posted a wider second quarter loss and also missed revenue expectations.
Vertex Pharma posts bigger 2Q loss
AP - Tue Jul 29, 4:07PM CDT
BOSTON (AP) — Vertex Pharmaceuticals Inc. on Tuesday reported a wider loss in its second quarter, and beat analysts' expectations.
Vertex Reports Second Quarter 2014 Financial Results and Provides Updates on Key Research and Development Programs
Business Wire - Tue Jul 29, 3:01PM CDT
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended June 30, 2014. Vertex reported total second quarter 2014 revenues of $138 million, including revenues of $113 million from KALYDECO(R) (ivacaftor). The GAAP net loss for the second quarter of 2014 was $(159) million, or $(0.68) per share. The non-GAAP net loss for the second quarter of 2014 was $(142) million, or $(0.61) per share. As of June 30, 2014, Vertex had $1.22 billion in cash, cash equivalents and marketable securities. In July 2014, Vertex entered into a credit agreement that provides for a secured loan of up to $500 million, $300 million of which Vertex received in July 2014, which adds to the company's cash balance. Vertex also reiterated its financial guidance for total 2014 non-GAAP revenues, 2014 KALYDECO revenues and non-GAAP operating expenses. The company also provided updates on its key research and development programs in cystic fibrosis (CF).
Stock Market News for July 29, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Jul 29, 9:10AM CDT
Benchmarks ended Monday’s choppy trading session little changed as investors assessed new deals and discouraging housing data
Will Vertex Pharmaceuticals (VRTX) Loss be Below Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 28, 3:30PM CDT
Vertex Pharmaceuticals Inc. (VRTX) is scheduled to report second quarter 2014 results after market close on Jul 29.
Should You Buy Vertex Pharmaceuticals (VRTX) Ahead of Earnings? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 28, 7:48AM CDT
Analysts raising estimates right before earnings is a pretty good indicator of some favorable trends underneath the surface for Vertex Pharmaceuticals.
Global Rheumatoid Arthritis Drugs Market 2014-2018
M2 - Mon Jul 28, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tv2rn2/global_rheumatoid) has announced the addition of the "Global Rheumatoid Arthritis Drugs Market 2014-2018" report to their offering. RA is a chronic disease that leads to inflammation and pain in the human body's joints such as wrists, fingers, knees, feet, and ankles. In addition, it causes inflammation of the tissues that surround the joints and in other organs. The symptoms of RA begin slowly, usually just mild pain around the joints coupled with stiffness and fatigue, and in the later stages it causes inflammation of the joints. It can occur at any age, even in children, which is called juvenile arthritis. The disease is three times more common in women than in men. Genetic and environmental elements are known to contribute in the development of RA. The analysts forecast the Global Rheumatoid Arthritis Drugs market will grow at a CAGR of 4.09 percent over the period 2013-2018. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Competitive Assessment of Top Drugs 08. Five Forces Analysis 09. Market Segmentation by Category 10. Geographical Segmentation 11. Buying Criteria 12. Rate of Incidence and Prevalence 13. Pipeline Snapshot 14. Market Growth Drivers 15. Drivers and their Impact 16. Market Challenges 17. Impact of Drivers and Challenges 18. Market Trends 19. Trends and their Impact 20. Vendor Landscape 21. Key Vendor Analysis 22. Other Reports in this Series Companies Mentioned: - AbbVie Inc. - Amgen Inc. - Bristol-Myers Squibb Co. - F. Hoffmann-La Roche Ltd. - Janssen Pharmaceuticals Inc. - Pfizer Inc. - AB Science SA - Astellas Pharma Inc. - AstraZeneca plc - Biogen Idec Inc. - Boehringer Ingelheim GmbH - Celgene Corp. - Daiichi Sankyo Co. Ltd. - Eli Lilly & Co. - GE Healthcare Co. - Genmab A/S - GSK plc - Incyte Corp. - Merck & Co. Inc. - Mitsubishi Tanabe Pharma Corp. - Novartis AG - Novo Nordisk A/S - Rigel Pharmaceuticals Inc. - Sanofi - Takeda Pharmaceutical Co. Ltd. - UCB SA - Vertex Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/tv...rheumatoid
MONDAY DEADLINE: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Vertex Pharmaceuticals Incorporated and Its Board of Directors and a Lead Plaintiff Deadline of July 28, 2014 -- VRTX
Business Wire - Fri Jul 25, 6:04PM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who purchased Vertex Pharmaceuticals Incorporated ("Vertex" or the "Company"
(NasdaqGS:VRTX) securities between May 7, 2012 and May 29, 2012. INVESTOR ALERT: Class Action Lawsuit Against Vertex Pharmaceuticals Incorporated Announced by Law Offices of Howard G. Smith
Business Wire - Wed Jul 23, 12:23PM CDT
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of all purchasers of the common stock of Vertex Pharmaceuticals Incorporated ("Vertex" or the "Company"
(NASDAQ:VRTX) between May 7, 2012 and May 29, 2012, inclusive (the "Class Period" . SmarTrend Watching for Potential Pullback in Shares of Vertex Pharmaceuticals After 1.48% Gain
Comtex SmarTrend(R) - Tue Jul 22, 5:13PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $95.75 to a high of $98.08. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $97.78 on volume of 1.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Vertex Pharmaceuticals Rises 1.48% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Jul 22, 5:11PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $95.75 to a high of $98.08. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $97.78 on volume of 1.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SHAREHOLDER ALERT: Brower Piven Encourages Investors With Losses Over $100,000 In Vertex Pharmaceuticals Incorporated To Contact The Firm Before The Lead Plaintiff Deadline In Class Action Lawsuit -- VRTX
GlobeNewswire - Tue Jul 22, 4:44PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of purchasers of Vertex Pharmaceuticals Incorporated ("Vertex" or the "Company"
(Nasdaq:VRTX) common stock during the period between May 7, 2012 and May 29, 2012, inclusive (the "Class Period" , and informs investors who wish to become proactively involved in the litigation that they have until July 28, 2014 to seek appointment as lead plaintiff. Biotech Stock Roundup: AbbVie Woos Shire with Revised Offer, Sarepta Slips on Eteplirsen Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 16, 8:49AM CDT
Focus last week remained on AbbVie's (ABBV) attempts to acquire Shire (SHPG) - the company came back with a revised offer which could very well be accepted by Shire.
SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Vertex Pharmaceuticals Incorporated and Its Board of Directors and a Lead Plaintiff Deadline of July 28, 2014 -- VRTX
GlobeNewswire - Wed Jul 16, 3:52AM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who purchased Vertex Pharmaceuticals Incorporated ("Vertex" or the "Company"
(Nasdaq:VRTX) securities between May 7, 2012 and May 29, 2012. INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against Vertex Pharmaceuticals Incorporated
Business Wire - Tue Jul 15, 7:32AM CDT
Glancy Binkow & Goldberg LLP reminds investors of Vertex Pharmaceuticals Incorporated ("Vertex" or the "Company"
(NASDAQ:VRTX) that all purchasers of Vertex common stock between May 7, 2012 and May 29, 2012, inclusive (the "Class Period" have until July 28, 2014, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit. 
